The Clinical Research Center
A Service of Retina Consultants of Minnesota
Dedicated to providing state-of-the-art treatment of eye diseases that cause vision loss by damaging the macula area of the retina.
About the Center
The Clinical Research Center is dedicated to advanced clinical research in the effort to find new and more effective treatments for Age-Related Macular Degeneration (AMD) and related diseases. We offer eligible patients who suffer from these diseases the opportunity to participate in a variety of clinical research trials that may offer access to advanced new treatments not yet available to the general public. A service of Retina Consultants of Minnesota (RCM), the Clinical Research Center is supported by fifteen Retina Specialists, a dedicated full-time clinical research staff, and the state-of-the-art retina treatment facilities of RCM.
Proven Experience
The Clinical Research Center is dedicated in fighting blindness through cutting-edge clinical research. We are one of the leading global centers committed to studying the vitreoretinal disorders.
Our dedicated research staff and advanced top of the line diagnostic imaging modalities and continues to pursue new advanced care to strengthen future care for patients with retinal disorders.
About Retina Consultants of Minnesota
The Clinical Research Center is the research division of Retina Consultants of Minnesota (RCM), one of the largest groups of physicians specializing in diseases of the macula, retina, and vitreous.
The physicians of RCM have over 200 years of cumulative experience in their field, have authored over 350 scientific articles, hold leadership positions in national and international professional organizations, and have been involved in research on the treatment of a variety of macular and retinal diseases since 1978.
Current Clinical Trials at RCM
Actively Enrolling
Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes and allow for less frequent eye injections when compared to an existing medication (aflibercept) in the treatment of macular edema associated with retinal vein occlusion.
Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes and allow for less frequent eye injections when compared to an existing medication (aflibercept) in the treatment of diabetic macular edema.
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy
Active Trials (Full)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with treatment-naïve neovascular (wet) age-related macular degeneration (nAMD).
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System with ranibizumab (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration
The purpose of this study is to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to DME.
This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME)
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).
Upcoming Trials
A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion
A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion
A phase IIIb/IV, multicenter, open-label, single-arm study of the efficacy and safety of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than ranibizumab
A randomized, partially masked, controlled, phase 2b/3 clinical study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with nAMD
